Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Intravesical drug-releasing systems
10 evidence topics · 4 sources
FDA-approved indication and mechanism: gemcitabine intravesical system
European guideline description of TAR-200
SunRISe-1 Cohort 2: design and population
SunRISe-1 Cohort 2: efficacy in the prescribing information
| Endpoint | Gemcitabine intravesical system |
|---|---|
| Participants | “N=83” |
| Complete response rate (95% CI) | “82% (72, 90)” |
| Duration of response, range in months | “0+, 44+” |
| Duration of response ≥12 months, % (n) | “51% (35)” |
| Basis of duration of response | “Based on patients (n=68) with a complete response at any time” |
SunRISe-1 Cohort 2: published complete response and duration of response
“The centrally confirmed CR rate in Cohort 2 was 82.4% (95% CI, 72.6 to 89.8), with 70 of 85 patients achieving CR” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After a median follow-up in responders of 20.2 months (range, 5-48), median DOR was 25.8 months (95% CI, 8.3 to not estimable” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among 70 responders, 37 (52.9%) had a DOR of ≥12 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
SunRISe-1 Cohort 4: papillary-only disease
“Fifty-two patients with BCG-unresponsive high-risk papillary disease–only NMIBC received TAR-200 monotherapy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The Cohort 4 primary end point was disease-free survival (DFS).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After a median follow-up of 12.8 months (range, 4-17), the median DFS was not estimable.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At 6, 9, and 12 months, DFS rates were 85.3% (95% CI, 71.6 to 92.7), 81.1% (95% CI, 66.7 to 89.7), and 70.2 (95% CI, 51.6 to 82.8), respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote